Dendritic cell maturation markers (DC maturation markers)

Dendritic cell (DC) maturation markers represent a diverse set of proteins, primarily cell surface receptors and co-stimulatory molecules, that characterize the transition of DCs from an immature, antigen-sampling state to a mature, antigen-presenting state (Worbs et al., 2017, Nature Reviews Immunology). Key markers include CD80, CD83, and CD86, as well as Major Histocompatibility Complex class II (MHC II/HLA-DR) molecules, which are upregulated to facilitate the activation and differentiation of naive T cells (Patente et al., 2019, Frontiers in Immunology). Additionally, the expression of the chemokine receptor CCR7 is a hallmark of maturation, enabling DC migration from peripheral tissues to secondary lymphoid organs (Banchereau & Steinman, 1998, Nature). While not a single therapeutic target, these markers are essential pharmacodynamic indicators in the development of immunotherapies, such as Toll-like receptor (TLR) agonists and cancer vaccines, which seek to enhance DC-mediated anti-tumor immunity (Steinhagen et al., 2011, Vaccine). Conversely, immunosuppressive agents like corticosteroids or CTLA-4 Ig (abatacept) function by inhibiting the expression or activity of these maturation markers to treat autoimmune diseases or prevent transplant rejection (Wakkach et al., 2003, Immunity). Because this term refers to a heterogeneous set of proteins rather than a single molecular entity, it is classified as a biomarker category rather than a specific therapeutic target.

Other names

Dendritic cell activation markersDC phenotypic markersMature dendritic cell markers